Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Justin Yovino of Ideal Face & Body
In May 2026, At the EASL Congress 2026, MetaVia presented promising late-breaking Phase 1 clinical trial results for DA-1726, an investigational dual GLP-1 and glucagon receptor agonist under development for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH)
This medication fosters lasting weight management through multiple mechanisms
The broader landscape of GLP-1 peptide medications is evolving rapidly, with newer compounds like retatrutide and mazdutide entering the picture
A more abstract risk is the reality that its so easy to get these meds without receiving actual medical care
US$ 21.69
US$ 26.20
US$ 20.34
US$ 22.49
US$ 22.08
